Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102...
” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. “Data from PDX tumor preclinical models has shown potent anti-tumor activity in multiple human cancer indications